PPMD's Blog – March 2012 Archive (4)
Prosensa’s Clinical Development Plan Update – March 2012
In parallel to the on-going development of the lead compound PRO051/GSK2402968, which is being developed by GSK with an active involvement of Prosensa, there are five more compounds for Duchenne in Prosensa’s pipeline. Below you can find an update about the current state of development of these compounds.
Prosensa is currently conducting a clinical study to investigate the effect of PRO044 in boys with Duchenne muscular dystrophy, who have a dystrophin gene mutation amenable to…
Added by PPMD on March 26, 2012 at 9:41am — 10 Comments
Important Webinar: AVI Clinical Trial Update
AVI Clinical Trial Update
Parent Project Muscular Dystrophy presents an AVI webinar on Wednesday, March 21 at 1pm eastern. The webinar will cover a pre-data update on AVI BioPharma's Phase IIb study evaluating eteplirsen for the treatment of Duchenne patients with mutations amenable to exon-51 skipping, and will be lead by Chris Garabedian, the CEO of AVI…
Added by PPMD on March 19, 2012 at 2:30pm — No Comments
Reminder: Register Today for 2012 West Coast Connect Meeting
By now we hope you have heard that Parent Project Muscular Dystrophy will be hosting our first West Coast Connect Meeting, April 13-15, 2012 in San Diego, CA at the…
ContinueAdded by PPMD on March 7, 2012 at 10:00am — No Comments
Vote for Duchenne in the 2012 Neuro Film Festival!
Latest Blog Posts
- Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
- Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne
- Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
- Roche Restarts RG62026 Phase 2/3 Study
- [WEBINAR] What is a Master Protocol?
- Santhera Shares Duchenne Community Update on SIDEROS Trial
- Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program
Most Popular Blog Posts
- April 25: FDA Advisory Committee Meeting for Eteplirsen - Live Webcast Information
- September 28: FDA Advisory Committee Meeting for Ataluren - Live Webcast Information
- Action ALERT: Urge Congress to Vote YES on 21st Century Cures Act
- Summit Receives Fast Track Designation from FDA for Ezutromid in the Treatment of Duchenne
- Ongoing Traumatic Stress
- PTC Therapeutics to Discuss Launch Plans for Emflaza™ (Deflazacort) during Community Call on Monday, May 8th at 3:00 PM EDT
- Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 & SRP-4053
Monthly Archives
2018
2017
- December (11)
- November (8)
- October (7)
- September (10)
- August (2)
- July (1)
- June (7)
- May (5)
- April (8)
- March (9)
- February (6)
- January (7)
2016
- December (5)
- November (4)
- October (11)
- September (7)
- August (5)
- July (7)
- June (5)
- May (3)
- April (10)
- March (7)
- February (5)
- January (9)
2015
- December (16)
- November (5)
- October (7)
- September (4)
- August (5)
- July (10)
- June (6)
- May (4)
- April (2)
- March (4)
- February (5)
- January (3)
2014
- December (5)
- November (3)
- October (5)
- September (3)
- August (2)
- July (9)
- June (6)
- May (7)
- April (40)
- March (17)
- February (2)
- January (3)
2013
- December (19)
- November (52)
- October (1)
- September (4)
- August (3)
- July (1)
- June (4)
- May (4)
- April (7)
- March (8)
- February (5)
- January (3)
2012
- December (3)
- November (2)
- October (4)
- September (2)
- August (1)
- July (1)
- June (1)
- May (2)
- April (1)
- March (4)
- February (8)
- January (1)
2011
2010
© 2019 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
